Introduction
PD-1 cDNA was originally isolated from a T cell hybridoma undergoing apoptotic cell death by phorbol ester and ionomycin (1) . The PD-1 gene belongs to the Ig gene superfamily and encodes a 55 kDa type I transmembrane protein (2) . Northern blot analysis revealed that the PD-1 gene is expressed exclusively in the thymus and to a lesser extent in the spleen (1) . In normal mice, PD-1 is expressed in a very small fraction of the thymocytes, which represent the transitional stage from the CD4 -CD8 -to CD4 ϩ CD8 ϩ population (3) . In the periphery, PD-1 expression is hardly detected on resting splenocytes but strongly induced on activated T and B cells (2) as well as activated myeloid cells (our unpublished data). PD-1 contains the so-called immunoreceptor tyrosine-based inhibitory motif (ITIM) (4, 5) , V/IxYxxL, in its cytoplasmic tail, which is conserved in the human Correspondence to: T. Honjo Transmitting editor: K. Okumura Received 15 June 1998, accepted 7 July 1998 counterpart as well (6, 7) . The family of receptors containing ITIM is expanding (8) . Among them, immunological receptors such as CD22, FcγRIIB and killer cell inhibitory receptors are well studied; the former two and the latter are shown to be involved in the negative regulation of signaling through the B cell receptor (BCR) and the cytotoxic receptors of NK cells respectively (5) . The negative regulation for the receptormediated signals of CD22 (9) is suggested to be mediated through the association with a protein tyrosine phosphatase, SHP-1 (10) (11) (12) (13) , which is shown to regulate BCR-mediated signaling (14) and to define a threshold for negative selection of B cell in the bone marrow (15) . FcγRIIB negatively regulates BCR-mediated signaling by SHIP (16) . Recently, CD5 has been proposed to be another type of negative regulator for peritoneal B lymphocyte (B-1 cell) function (17) .
In the present study, we have generated PD-1-deficient (PD-1 -/-) mice in order to examine the roles which PD-1 might play in immune responses in vivo. PD-1 -/-mice exhibited moderate splenomegaly, augmented proliferative response of B cells against anti-IgM antibodies in vitro and selective increase in the serum IgG3 as well as specific IgG3 antibody response to a T-independent (TI-2) antigen. Concomitantly, the expression of CD5 was significantly down-regulated in the peritoneal B-1 cell population of PD-1 -/-mice. The results suggest that PD-1 may be involved in the negative control of proliferation, differentiation and class switching of B cells.
Methods
Gene targeting and generation of PD-1 -/-mice A genomic fragment containing exons 2-5 of the PD-1 gene was cloned from a genomic library derived from 129/SV mice (18) . The 5.4 kb KpnI-EcoRV fragment extending upstream from the EcoRV site in exon 3 and the 4.1 kb PvuII fragment extending downstream from the PvuII site in exon 5 were cloned between the NotI and SmaI sites and between the ClaI and XhoI sites respectively of pBluescript SK -(Stratagene, La Jolla, CA). The PGK-neo r cassette (19) was cloned in the opposite direction between the EcoRV and HindIII sites of the resulting vector. This targeting vector was linearized with XhoI. Cells of the embryonic stem (ES) line, D3, were transfected with the linearized vector by electroporation (230 mV, 500 F) (BioRad, Hercules, CA). At 48 h after electroporation, transfectants were screened by culture with 0.3 mg/ml of G418 (Gibco/BRL, Rockville, MD). Neo-resistant colonies were examined by Southern hybridization for homologous recombination events. Out of 969 clones screened, five clones containing the targeted allele were isolated and injected into blastocytes. One clone, H20, generated male chimeras and transmitted the mutant allele into the germline. Mice C57BL/6 (B6) mice were purchased from Japan SLC (Shizuoka, Japan). PD-1 -/-mice were backcrossed at least eight generations into C57BL/6 mice for analysis. These mice were maintained in our specific pathogen-free facility of the Institute of Laboratory Animals, Faculty of Medicine, Kyoto University.
Antibodies
Anti-mouse PD-1 mAb was biotinylated as described previously (2) . The following mAb were purchased from PharMingen (San Diego, CA): phycoerythrin-R (PE)-conjugated anti-CD4 (RM4-5), FITC-labeled anti-mouse CD3 (145-2C11), FITC-labeled anti-mouse CD25 (7D4), FITC-labeled and biotinylated anti-mouse CD45R/B220 (RA3-6B2), PEconjugated anti-mouse CD44 (1M7), PE-conjugated antimouse CD11b (Mac1) (M1/70), FITC-labeled anti-mouse Gr-1 (Ly-6G), biotinylated anti-mouse CD5 (53-7.3) and biotinylated anti-mouse TCRδ (GL3). Anti-mouse CD8a-FITC (53-6.7) and streptavidin (SA)-conjugated Red670 were obtained from Gibco/BRL. FITC-labeled anti-IgM polyclonal antibodies were purchased from Cappel (Durham, NC).
Flow cytometry
Cells were suspended in a staining buffer containing PBS, 2% FCS and 0.2% azide, pre-incubated with 2.4G2 (anti-Fc receptor mAb) to prevent non-specific binding, and then incubated on ice for 20 min with indicated staining reagents at saturating concentrations. For the three-color staining, the cells were incubated with Red670-SA for 15 min, washed and resuspended in 500 µl of the staining buffer. Analysis was performed using FACSCalibur (Becton Dickinson, San Jose, CA) and CellQuest (Becton Dickinson). In total 20,000 events were collected, and viable cells were determined by forward and side scatters. The condition of set quadrants was determined using control staining. The contour profiles were shown with 10% probability.
Proliferation assay
Splenocytes from three mice of each genotype were pooled and examined to minimize individual differences. Splenic B cells were purified by complement-mediated lysis in combination with anti-Thy-1, CD4 and CD8 (3.155) mAb. Splenic T cells were obtained by panning with goat anti-mouse IgM antibodies. These cells (1ϫ10 5 /well) were cultured in 0.2 ml of complete RPMI medium (Gibco/BRL) containing 10% FCS with indicated stimuli for 72 h in 96-well flat-bottom plates (Iwaki, Chiba, Japan). Proliferation was assessed by the incorporation of 3 H-labeled thymidine (Amersham Life Science, Amersham, UK) added at 0.5 µCi/well during the last 18 h.
Immunization of mice
Twelve-week-old mice were immunized i.p. with 5 µg of DNPconjugated Ficoll in complete Freund's adjuvant (CFA; Nakarai Tesque, Kyoto, Japan) at day 0. Animals were bled at day 0, 7 and 14. Blood was let stand at room temperature overnight and then centrifuged at room temperature. Sera were stored at -20°C.
ELISA assay ELISA assay was conducted using affinity-purified mouse IgM, IgG1, IgG2a, IgG2b, IgG3 and IgA (Southern Biotechnology, Birmingham, AL) to generate standard curves. To determine titers of Ig and hapten-specific antibody in serum, 10 µg of goat anti-mouse isotype-specific antibodies (Southern Biotechnology) and hapten-conjugated BSA were plated respectively. Appropriate dilution sets of serum samples were then loaded for 2 h, followed by the addition of alkaline phosphatase-conjugated anti-mouse isotype-specific antibodies (Southern Biotechnology). ELISA color development was performed using phosphatase substrate 104 (Sigma, St Louis, MO). The OD values were determined by comparing the values within the linear range of standard curves and diluted samples.
Results

Generation of PD-1 -/-mice
The PD-1 gene consists of five exons. To disrupt the PD-1 gene, a part of exon 3, exon 4 and a part of exon 5 were replaced with the neo r gene in a targeting vector, which Seven each of PD-1 ϩ/ϩ and PD-1 Ϫ/Ϫ mice were examined as described in the legend to Fig. 2(B) . Cell numbers are shown as ϫ10 7 except that Mac1 ϩ GR ϩ cell numbers are shown as ϫ10 5 . should result in the deletion of both transmembrane and cytoplasmic regions of the PD-1 molecule (Fig. 1A) . Chimeric mice were obtained by the microinjection of PD-1 genedisrupted ES cells as described in Methods. Southern hybridization of BamHI-digested genomic DNA of the offsprings from chimeric mice revealed a 17 kb band from the wild-type allele and an expected 14.5 kb band from the mutant allele (Fig. 1B) with probe a (see Fig. 1A ) and only the latter hybridized with the neo r probe. Also upon digestion with EcoRV, a 6.5 kb band from the wild-type allele and a 8.5 kb band from the mutant allele were detected with a probe ex2 as expected. Littermate mating generated homozygous mutant mice which contained only the mutated allele (Fig.  1B) . While PD-1 expression was induced on the thymocytes from wild-type mice stimulated with phorbol myristate acetate (PMA) plus ionomycin, immobilized anti-CD3 mAb or concanavalin A (Con A) as shown previously (2) , no expression of PD-1 was induced on thymocytes from the mutant homozygotes (Fig. 1C) . PD-1 expression was not detected on the CD4 -CD8 -thymocyte subset from the mutant mice either (data not shown), while PD-1 is expressed on CD4 -CD8 -thymocytes of normal mice (2) . These data demonstrated that PD-1 expression was indeed deficient in the homozygous mutant mice.
Moderate splenomegaly with increased numbers of B cells and myeloid cells in PD-1 -/-mice PD-1 -/-mice grew up normally and looked healthy. Macroscopically, however, they consistently exhibited moderate splenomegaly as compared with PD-1 ϩ/ϩ littermates (123.21 Ϯ 43.4 versus 67.5 Ϯ 11.5 mg, P Ͻ 0.005) ( Fig. 2A) associated with a proportional increase in the total cellularity (18.5 Ϯ 6.15ϫ10 7 versus 10.8 Ϯ 2.46ϫ10 7 , P Ͻ 0.05). Flow cytometric analysis indicated that the relative proportion of splenic CD3 ϩ T cells in PD-1 -/-mice was reduced while that of B220 ϩ B cells was unchanged or slightly reduced (Fig. 2B) . Consequently, the absolute number of B220 ϩ B lineage cells in the spleen was significantly increased in PD-1 -/-mice as compared with control littermates (Table 1 ). There was no alteration in the ratio of pre-B (IgM -) to B (IgM ϩ ) in the B lineage nor the ratio of CD4 ϩ to CD8 ϩ subpopulation in the T lineage cells (Fig. 2B and Table 1 ). Mac1 ϩ Gr1 ϩ cells, on the other hand, were significantly increased in terms of both relative frequency and absolute number (Fig. 2B and Table  1 ). It thus appears that splenomegaly in the PD-1 -/-mice is mostly contributed by the increased cellularity of B lineage and myeloid cells. As for the thymus, no significant change was observed in both total cellularity and distribution of thymocyte subsets as judged by the expression of CD4, CD8, αβTCR-CD3, CD44, CD25 and CD69 (data not shown).
Enhanced proliferative response of splenic B cells to anti-IgM antibodies but not of T cells to the 145-2C11 anti-CD3 mAb in spleen cells from PD-1 -/-mice Proliferative response of peripheral lymphocytes by antigen receptor cross-linking was examined in vitro using the anti-CD3 mAb and anti-IgM antibodies. Freshly isolated splenic T and B cells from PD-1 -/-as well as their littermates (PD-1 ϩ/ϩ and PD-1 ϩ/-) were cultured for 3 days in the presence of varying concentrations of the anti-CD3 mAb and anti-IgM (F(abЈ) 2 ) antibodies respectively, and DNA synthesis was assessed. As shown in Fig. 3(A) , PD-1 -/-splenic T cells exhibited a proliferative response to the anti-CD3 mAb comparable with those from control mice. On the other hand, splenic B cells from PD-1 -/-mice showed a significantly augmented proliferative response to anti-IgM antibodies as compared with those from PD-1 ϩ/ϩ mice (Fig. 3B) . Interestingly, splenic B cells from PD-1 ϩ/-mice also exhibited an augmented response, although slightly less than those from PD-1 -/-mice, implicating the gene dosage effect. Spleen cells from all three genetic groups, on the other hand, showed a comparable proliferative response to lipopolysaccharide (LPS) or PMA plus ionomycin (Fig. 3C ).
Elevated IgG3 levels in the serum of PD-1 -/-mice Facilitated by the above observations, we then assessed the levels of serum Ig in PD-1 -/-mice. As summarized in Fig. 4 , no significant difference in the levels of serum IgM and IgG1 was observed among PD-1 -/-, PD-1 ϩ/-and PD-1 ϩ/ϩ mice. IgG2b and IgA, on the other hand, tended to be increased in PD-1 -/-mice as compared with PD-1 ϩ/ϩ mice (1212.3 Ϯ 455.6 versus 556.7 Ϯ 277.0 µg/ml, P Ͻ 0.05 and 17.4 Ϯ 6.1 versus 7.9 Ϯ 3.3 µg/ml, P ϭ 0.05 respectively). Most strikingly, the serum IgG3 level was increased in PD-1 -/-mice by as much as 3 times as compared with that in PD-1 ϩ/ϩ mice (380 Ϯ 122 versus 117 Ϯ 66.3 µg/ml), which was statistically significant (P Ͻ 0.01). PD-1 ϩ/-littermates again showed, on average, an intermediate level of serum IgG3 between PD-1 ϩ/ϩ and PD- 1 -/-mice. IgG2a was undetectable in the sera from all groups.
Augmented IgG3 antibody response against a T-independent antigen in PD-1 -/-mice.
IgG3 is believed to be the major Ig isotype produced in response to so-called T-independent antigens (20) . We therefore examined the antibody response in vivo against a representative TI-2 antigen, DNP-Ficoll, in PD-1 -/-mice. PD-1 -/-mice as well as their PD-1 ϩ/-and PD-1 ϩ/ϩ littermates were immunized with 5 µg DNP-Ficoll in CFA, and the primary anti-DNP IgM and IgG antibodies in the sera were assayed 1 and 2 weeks after the immunization. As shown in Fig. 5(A) , the anti-DNP IgM response was indistinguishable among PD-1 -/-and control littermates. In contrast, PD-1 -/-mice showed a significantly higher anti-DNP IgG antibody response than PD-1 ϩ/ϩ littermates (194.8 Ϯ 65.8 versus 91.9 Ϯ 51.4 U/ml, P Ͻ 0.05). PD-1 ϩ/-mice tended to show a slightly higher anti-DNP IgG response (110.8 Ϯ 47.9 U/ml) than PD-1 ϩ/ϩ mice, but the difference was statistically insignificant. Subclass analysis of the anti-DNP IgG antibody at 2 weeks indicated that the anti-DNP IgG3 was indeed significantly greater in PD-1 -/-than PD-1 ϩ/ϩ mice (74.9 Ϯ 14.0 versus 44.7 Ϯ 14.7 U/ml, P Ͻ 0.05), while the anti-DNP IgG1 level was comparable (Fig. 5B) . The average anti-DNP IgG3 level in PD-1 ϩ/-mice was again between those of PD-1 ϩ/ϩ and PD-1 -/-mice (72.0 Ϯ 23.7 U/ml). No significant change was observed in the antibody response in vivo against a TD antigen, NP-human gamma globulin, among the three groups, all of which produced indistinguishable levels of IgM and IgG anti-NP antibodies in the sera (data not shown). Table 2) . This was largely due to an increase in CD5 ϩ IgM -(T) cells in PD-1 -/-mice (38ϫ10 4 versus 8ϫ10 4 ). Similarly, the total number of Mac1 ϩ IgM ϩ (B-1) cells tended to increase in PD-1 -/-mice (32ϫ10 4 versus 28ϫ10 4 ). Quite unexpectedly, however, CD5 ϩ IgM ϩ cells were rather decreased (17ϫ10 4 versus 23ϫ10 4 ). Consequently, on average only around half of Mac1 ϩ IgM ϩ cells were expected to be CD5 ϩ in PD-1 -/-mice, while Ͼ80% of them were CD5 ϩ in control mice. To confirm this, three-color analysis was performed. As shown in Fig. 6 , the proportion (47.0 versus 66.4%) and the peak fluorescence intensity (143 versus 229) of CD5 ϩ cells in the Mac1 ϩ IgM ϩ population were apparently decreased in PD-1 -/-mice as Four each of PD-1 ϩ/ϩ and PD-1 Ϫ/Ϫ mice were examined as described in the legend to Fig. 6 . Cell numbers are shown as ϫ10 4 . Percentages are shown in parentheses.
Reduced CD5 expression in the Mac1
compared with control mice. The results suggested that CD5 expression was significantly down-regulated in the B-1 cell population in PD-1 -/-mice.
Discussion
The PD-1 antigen is hardly expressed on the normal lymphoid cells except for a very small population of thymocytes representing γδ T cells and the transitional stage of cells from CD4 -CD8 -to CD4 ϩ CD8 ϩ of the αβ T cell lineage (3). The expression, however, is strongly induced on the majority of thymocytes as well as peripheral lymphocytes of both T and B lineages following antigen receptor cross-linking (2). More recently, it was found that PD-1 was also expressed on activated myeloid cells (our unpublished data). Thus PD-1 can be classified as a so-called activation antigen. Although PD-1 belongs to the Ig superfamily transmembrane protein bearing the ITIM motif, its functions remain to be seen. In the present study, we have generated PD-1 -/-mice to analyze the biological roles of PD-1 in vivo.
PD-1 -/-mice developed and grew apparently normally. Careful immunological analyses, however, revealed several features distinct from littermate control mice. PD-1 -/-mice showed moderate but consistent splenomegaly with approximately twice the cellularity as compared with control littermates of the same specific pathogen-free colony, while no difference was observed in the size and cellularity of thymus. Although all cellular components appeared to be more or less increased in the spleens of PD-1 -/-mice, a significant increase was noted in B and myeloid (Mac1 ϩ Gr1 ϩ ) cells. Consistent with the observation, splenic B cells (Fig. 3 ) and myeloid cells (unpublished data) from PD-1 -/-mice exhibited a significantly augmented proliferative responses in vitro to stimulation with anti-IgM antibodies and granulocyte macrophage colony stimulating factor respectively as compared with those from littermate controls, while the splenic T cell response to the anti-CD3 mAb was comparable. The results imply that PD-1 contributes to the homeostatic control for the normal cellularity of B and myeloid cells in the periphery in vivo.
The serum Ig level was moderately increased in PD-1 -/-mice as compared with the littermate controls. Class and subclass analyses revealed that IgA, IgG2b and most significantly IgG3 were increased, while IgM and IgG1 levels were comparable to the controls. We therefore examined the antibody responses of PD-1 -/-mice in vivo against both TD and TI-2 antigens. Results indicated that, although PD-1 -/-mice exhibited comparable antibody responses to the TD antigen with littermate controls, antibody responses to the representative TI-2 antigen (DNP-Ficoll) were significantly augmented in PD-1 -/-mice. Furthermore, subclass analysis of the specific anti-DNP antibody indicated that IgG3 was again selectively and significantly increased in PD-1 -/-mice as compared with littermate controls while IgM and IgG1 remained comparable.
It is generally considered that the B-1 cell population is primarily, if not exclusively, responsible for the antibody response to TI-2 antigens of carbohydrate nature, which directly activate B-1 cells by mutivalent interaction (20) . Murine B-1 cells are characterized by the distinct phenotypes (Mac1 ϩ CD5 ϩ ) from conventional B2 cells and are present most abundantly in the peritoneal cavity (21) . The number of Mac1 ϩ IgM ϩ cells in the peritoneal cavity of PD-1 -/-mice was slightly increased as compared with age-matched controls. Curiously, however, the number of CD5 ϩ IgM ϩ cells was rather decreased in PD-1 -/-mice ( Fig. 6 and Table 2 ). Consequently, the ratio of CD5 ϩ IgM ϩ to Mac1 ϩ IgM ϩ cells was significantly reduced in PD-1 -/-mice (52%) as compared with littermate controls (85%). Indeed, three-color analysis indicated that not only the frequency of CD5 ϩ cells but also their peak intensity of CD5 expression in the Mac1 ϩ IgM ϩ cell population was clearly reduced in PD-1 -/-mice, although the possible presence of a very minor Mac1 -CD5 ϩ IgM ϩ population remained to be carefully examined.
At present, the exact meaning for such a discrepancy between Mac1 and CD5 expression in the B-1 population remains to be further investigated. It has been previously proposed that the murine B-1 cell population was divided into the B-1a (Mac1 ϩ CD5 ϩ ) and B-1b (Mac1 ϩ CD5 -) subpopulations (22, 23) . There are, however, also indications that the CD5 antigen represents the state rather than the lineage marker of B-1 cells (24, 25) . Since the intensity of CD5 expression was clearly reduced even in the the CD5 ϩ fraction of the Mac1 ϩ IgM ϩ population, we tend to consider that the increased CD5 -Mac1 ϩ B-1 cells in PD-1 -/-mice simply reflected the general down-regulation of CD5 expression in vivo. In as much as CD5 is shown to function as a negative regulator for BCR-mediated signaling in B-1 cells (17) , it may be implied that B-1 cells in PD-1 -/-mice are preactivated in vivo. In this aspect, it is noted that the frequency of CD44 high memory type T cells is also significantly increased in PD-1 -/-mice as compared with littermate control mice (our unpublished observation).
In conclusion, mice deficient of the PD-1 gene exhibited several characteristic phenotypes, including moderate hyperplasia of multiple lymphohematopoietic cells, selective increase in serum IgG3 as well as TI-2 antigen-induced IgG3 antibodies and the phenotypical alteration of the peritoneal B-1 cell population. It remains to be carefully investigated whether these alteration are in any way causatively related with each other. Nonetheless, taken together with the fact that PD-1 also has the ITIM motif in the cytoplasmic tail and is strongly induced following lymphocyte activation (2), it is tempting to speculate that PD-1 functions as one of the negative regulators for lymphocyte signaling at distinct stages, most likely after the activation by antigens, including class switching.
It is well known that autoantibodies of the IgG3 isotype have a much higher tendency to be deposited in organs such as the kidney to induce overt immune complex diseases than those of other isotypes in mice and thus IgG3 autoantibodies are often called 'nephritogenic antibodies' (26) (27) (28) . Thus, the genetic trait for selective increase in both natural and TIantigen-inducible IgG3 antibodies in the absence of PD-1 might well contribute to the development for the immune complex diseases if combined with other genetic traits for autoantibody production. Indeed, we have recently observed that B6-lpr/lprϫPD-1 -/-mice developed much severer proliferative glomerulonephritis than B6-lpr/lpr mice with accelerated generalized lymphadenopathy (manuscript in preparation), implicating the synergistic effect between the mutation in the PD-1 and Fas genes in the pathogenesis. Development of systemic autoimmune diseases in humans and mice is certainly under complex polygenic control (29) , and further analysis for the PD-1 gene and its functions might provide a clue to dissect out the complex events leading to the overt pathogenic manifestation of autoimmune diseases in humans. 
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